By combining machine learning, theoretical physics and computational medicinal chemistry, the technologies developed within the start-up make it possible to generate active molecules for a given therapeutic target. Aqemia stands out on the market for the quality and speed of its calculation of affinity between active ingredient and protein of interest and its generative AI algorithms which allow it to explore an innovative chemical space in collaboration with pharmas and biotech.
Original laboratory: PASTEUR Laboratory, École Normale Supérieure - PSL, CNRS, Sorbonne University
Establishments: ENS - PSL
Co-founders: Maximilien Levesque (CEO) and Emmanuelle Martiano (COO)
Disruptive technology for drug discovery: the journey from laboratory to spinoff
